JPMorgan Downgrades Pliant Therapeutics Amid Strategic Uncertainty
JPMorgan cuts Pliant Therapeutics to Underweight rating as the biotech company searches for direction after discontinuing its main drug program earlier this year.
/ 933 items
#Healthcare↓
JPMorgan Initiates Cidara Stock Coverage with $200 Price Target on Flu Drug Potential
JPMorgan sets $200 price target for Cidara Therapeutics, citing "game-changing" flu treatment CD388 with projected $4B peak U.S. sales and 75% success probability
Shuttle Pharma Signs $10M Deal to Acquire AI Drug Discovery Platform Molecule.ai
Shuttle Pharmaceuticals announces letter of intent to acquire Molecule.ai, an AI-powered platform transforming drug discovery through machine learning and autonomous workflows.
TrumpRx Expands: Drugmakers, Pharmacies, and GoodRx Join the Discount Site
The Trump administration is working on "TrumpRx," a new site connecting consumers to drugmakers, pharmacies, and discount programs like GoodRx to help lower prescription costs.
Cabaletta Bio Shows Promising Results for Autoimmune Disease Treatment Without Chemotherapy
Cabaletta Bio's rese-cel achieves complete B cell depletion and rapid symptom improvement in pemphigus vulgaris patients without preconditioning.
Jefferies Initiates Beam Therapeutics with Buy Rating on Promising Gene Therapy Pipeline
Jefferies sets $41 price target for Beam Therapeutics, highlighting BEAM-302's potential as one-time treatment for rare genetic disease with $2.5B peak sales opportunity.